Live Breaking News & Updates on Area Lead Haematology

Stay updated with breaking news from Area lead haematology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy Expanded indication for this one-time infusion may provide pati. ....

Region Flamande , Edmond Chan , Drug Administration , European Union , Committee For Orphan Medicinal Products , Janssen Cilag International , European Medicines Agency , European Commission , Area Lead Haematology , Johnson Innovative , New England Journal , Professor Jes , San Miguel , Translational Medicine , Universidad De Navarra , Jordan Schecter , Vice President , Disease Area Leader , Multiple Myeloma , Orphan Medicinal Products , Product Characteristics , Innovative Medicine ,

Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy

Media contact:

Investor contact:

. ....

United States , Region Flamande , Edmond Chan , Jenni Mildon , Ciltacabtagene Autoleucel , European Commission Grants Conditional Approval , Legend Biotech United States Inc , Janssen Biotech Inc , Drug Administration , American Society Of Clinical Oncology , European Commission , Janssen Cilag International , Chinese Company Legend Biotech To Develop Investigational , American Cancer Society , Committee For Orphan Medicinal Products , Janssen Research Development , Johnson Company , European Union , European Medicines Agency , Exchange Commission , Cilag International , Area Lead Haematology , Johnson Innovative , New England Journal , Professor Jes , San Miguel ,

Janssen Receives Positive CHMP Opinions for Novel

Talquetamab is the first therapy targeting GPRC5D to receive a positive CHMP Opinion Teclistamab, the first BCMA-targeting bispecific antibody to. ....

United States , Region Flamande , United Kingdom , Sen Zhuang , Edmond Chan , Committee For Medicinal Products Human Use , None Of The Janssen Pharmaceutical Companies , American Society Of Clinical Oncology , European Medicines Agency , European Hematology Association , Drug Administration , European Commission , Janssen Research Development , Janssen Pharmaceutical Companies Of Johnson , Exchange Commission , Clinical Research , American Cancer Society , Companies Of Johnson , Janssen Pharmaceutical Companies , Medicinal Products , Human Use , Senior Director , Area Lead Haematology , Clinical Oncology , Annual Meeting , Hematology Association ,

CHMP Recommends Talquetamab Monotherapy for R/R Multiple Myeloma

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended conditional marketing authorization of talquetamab for use as a single agent in adult patients with relapsed or refractory multiple myeloma who have previously received at least 3 therapies. ....

Edmond Chan , Therapeutic Area Lead Haematology At Janssen Cilag , European Medicines Agency , Medicinal Products , Human Use , Area Lead Haematology , Janssen Cilag Limited , Adult Patients With Relapsed Or Refractory Multiple Myeloma Who Have Previously Received At Least 3 Therapies , Monumental 1 Study ,

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) Reduces

At 16 months median follow-up, cilta-cel significantly improved progression-free survival compared to two standard of care treatment regimens1 . ....

United States , Region Flamande , Ciltacabtagene Autoleucel , Edmond Chan , American Society Of Clinical Oncology Annual Meeting , European Medicines Agency , American Cancer Society , Congress Abstract , Janssen Biotech Inc , Janssen Research Development , Janssen Pharmaceutical Companies , American Society Of Clinical Oncology , European Hematology Association , European Commission Grants Conditional Approval , Legend Biotech United States Inc , None Of The Janssen Pharmaceutical Companies , Exchange Commission , Companies Of Johnson , Drug Administration , Janssen Pharmaceutical Companies Of Johnson , New England Journal , Clinical Oncology , Annual Meeting , Thenew England Journal , Hybrid Congress , Professor Jes ,